Editorially reviewed by Dr Fatimah Khan, registered with the Pakistan Medical and Dental Council (PMDC no. 104595-P). Editorial medical reviewer; does not prescribe or review patient assessments.
Review details
Review recorded:
Review scope: This article edition.
Editorial reviewer for Prescrivia. Editorial review does not establish participation in patient consultations.
Clinical review does not replace individual medical advice. Prescrivia is a technology intermediary; independent doctors make clinical decisions.
Legal review: Qualified review pending.
Language review: Qualified review pending.
Source and review
Source published:
Attributed source update:
Text edited:
Editorial role: Editorial team. This description does not establish an individual credential or clinical review of this edition.
Read our editorial policy and corrections. Edit dates and source descriptions do not establish qualified review.
What is zanamivir used for?
Zanamivir is an antiviral medicine for influenza. Relenza is inhaled through a special device; Dectova is given by intravenous infusion in hospital for selected serious cases. These are not interchangeable ways to self-treat ordinary flu.
The decision depends on the illness, timing, patient and current local guidance. An antiviral does not replace influenza vaccination or guarantee recovery.
Inhaled Relenza: timing and patient restrictions
The cited UK Relenza leaflet covers treatment from age five and describes starting promptly, within 48 hours of first symptoms for adults and within 36 hours for children. Other jurisdictions' licences can differ.
Treatment and prevention after exposure have different instructions. A clinician should choose the correct regimen; a general guide cannot turn one schedule into the other.
Tell the prescriber about asthma, COPD, other breathing problems, pregnancy, breastfeeding and all medicines. Severe or worsening flu requires assessment rather than waiting for a routine online request.
Diskhaler instructions: use the complete leaflet
Relenza powder must be inhaled using its Diskhaler. It is not a liquid for a nebuliser and should not be administered through another delivery device.
Use the full manufacturer patient leaflet and illustrated Diskhaler instructions, including the device guide at the end. Ask a pharmacist to demonstrate it and check that you can use it correctly.
The full instructions cover loading, piercing and rotating the Rotadisk, as well as preparing the prescribed number of inhalations. If any step is unclear, have a pharmacist check your technique before use.
Breathing difficulty: stop and get help
The leaflet warns about throat or chest tightness and breathing difficulty during use, including bronchospasm. Stop Relenza and get medical help immediately if these occur. Severe breathing difficulty or collapse requires emergency care.
Do not simply use a reliever inhaler and continue Relenza without assessment. If a clinician has prescribed Relenza for someone who uses other inhalers, follow the specific supervision and inhaler instructions they provide.
The powder contains lactose with milk protein. Milk-protein allergy is a stated exclusion; it is not the same question as lactose intolerance, which also requires discussion under the leaflet.
IV Dectova is a hospital treatment
EMA authorises Dectova for complicated, potentially life-threatening influenza in adults and children from six months when resistance is suspected or other antivirals, including inhaled zanamivir, are unsuitable.
Hospital specialists administer and monitor it; kidney function can affect the dose. It is not a routine alternative available through an outpatient medicine request.
The choice between antivirals cannot be settled by a generic statement that zanamivir is preferred. Resistance, breathing risks, route and the severity of illness need clinical assessment.
Information and clinical decisions
This guide provides general information, not a diagnosis or personal treatment plan. Any clinical assessment and prescribing decision rests with an independent clinician. Prescrivia is a technology intermediary, not a medical provider or pharmacy; it does not prescribe, sell or dispense medicines. Assessment does not guarantee a prescription, medicine availability or a health outcome.
Further reading: treatment information.
Read about online consultations and their limits. Service information must not delay urgent local care.
Sources
- Relenza UK product information — UK treatment/prevention distinction, age and timing, route restrictions, breathing risks and milk-protein allergy.
- Relenza full UK patient leaflet and illustrated Diskhaler guide — Complete device instructions and stop/get-immediate-help response to breathing or chest/throat symptoms.
- EMA: Dectova — Hospital IV treatment for selected complicated, potentially life-threatening influenza from age six months; not routine outpatient flu treatment.
- EMA: Dectova product information — Specialist administration, indication limits and renal-adjusted hospital prescribing.
See the current clinical, legal and language review statuses for this edition. Source checks are editorial work, not approval.